Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management
EASL · 2026 · Europe
Source and licence
- Authors
- Willem Pieter Brouwer, Luisa Vonghia, Maja Thiele et al.
- Title
- Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management
- Journal
- JHEP Reports, 2026
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC13521106
Licence statement of the original publication
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.
Abstract
Steatotic liver disease (SLD) is a spectrum of highly prevalent liver diseases encountered at many different healthcare levels. Awareness about metabolic dysfunction-associated SLD (MASLD), MetALD (MASLD and increased alcohol intake) and ALD (alcohol-related liver disease) is increasing beyond hepatology, as reflected by the various SLD guidelines issued by scientific societies from different disciplines, including endocrinology. The guidance presented here aims to improve cross-disciplinary knowledge and know-how by providing guidance to healthcare professionals from a global, holistic, multi-society and multi-stakeholder perspective. The patient trajectory was used as an overarching anchor point to ensure uniform guidance at all points along the SLD spectrum, with the ultimate goal of improving patient identification and optimising care. This consensus guidance covers patient identification and risk stratification, relevant cross-disciplinary primary and secondary care approaches, referral to and from tertiary care and strategies for disease management and monitoring.
Contents of the original publication
The section headings of the original.
- Introduction
- Methodology
- Screening and case-finding strategies
- Preventive and societal measures to combat liver disease
- Case-finding and risk stratification: Who, how and where
- Different scenarios for management of patients at high risk of fibrosis after targeted screening in primary care
- Low-resource settings and socioeconomic disparities in SLD
- Management at different stages of SLD
- Multidisciplinary approach
- How to approach SLD at different levels of healthcare: Primary care
- How to approach SLD at different levels of healthcare: Metabolic health specialists (diabetologists, endocrinologists and obesity specialists)
- How to approach SLD at different levels of healthcare: Hepatologist
- How to approach SLD at different levels of healthcare: The paediatrician
- Structured lifestyle intervention for SLD (Fig. 6)
- Motivation and information - a patient perspective
- Flexible systems with different levels of approach, from the minimum basis to the ideal solution
- Cirrhosis and compensated advanced chronic liver disease
- Definition of cACLD
- How to diagnose cACLD/cirrhosis – (non-)invasive tests
- How to assess portal hypertension and clinically significant portal hypertension in MASLD cACLD/cirrhosis
- HCC surveillance in MASLD cACLD/cirrhosis
- Prevention of liver decompensation and liver-related complications in MASLD-related cACLD/cirrhosis
- Nutrition in MASLD cACLD/cirrhosis
- The importance of physical activity in MASLD-related cACLD
- Surgery in MASLD-related cACLD
- Liver transplantation in MASLD cACLD/cirrhosis
- Safety considerations for statins, antidiabetic and anti-obesity medications in MASLD-related cACLD
- Specific MASH treatment
- Conclusions
- Financial support
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint